A Pfizer and Cytel veteran on why statisticians belong at trial design, and why fewer sponsors keep them in-house.
- How AI Is Used To Predict Trial Performance Before Enrollment
- Two Planning Mistakes That Quietly Sink Clinical Programs
- Token Costs Will Decide Clinical Supply AI
- A Framework For Diagnosing Clinical Research Technology Maturity
- Clinical Trial Sites Don't Need More Tech, They Need Fewer Silos
- A Biostatistician's Caution Around Digital Twins In Trials
- Who Owns Data Quality? The Authority Gap Slowing Trials
- Clinical Research Isn't Even A Recognized Job. That's A Problem.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Trends In Clinical Trials In 2025: Navigating A Transformative Landscape
In 2025, it is likely the clinical trial landscape will be shaped by advancements in artificial intelligence (AI), evolving recruitment strategies, and a renewed focus on equitable access.
-
Emerging Biopharm Rapidly Sets Up Phase 1 Oncology Trial
Uncover how an emerging biopharmaceutical company was able to expedite the initiation of a Phase 1 oncology trial for a novel treatment targeting relapsed/refractory multiple myeloma.
-
Building Patient-Focused eCOA Strategies: Insights And Best Practices
Discover why the use of electronic clinical outcome assessments (eCOA) in clinical research is becoming an increasingly important part of study design in this article.
-
Benefits Of Implementing EDC & Medical Coding With RTSM
Discover what happened when the Fountayn Platform, including RTSM, was used to support a client’s two-year, Phase III study seeking a cure for multiple sclerosis.
-
3 Proven eConsent Implementation And Adoption Best Practices
By advocating these three essential best practices, learn how stakeholders can navigate the complexities of eConsent adoption with confidence and enhance the overall efficiency and success of clinical trials.
-
Achieving Self Sufficiency In Data Collection For Optinose
Uncover how this specialty pharmaceutical company was able to gain control over its EDC environment by adopting a solution their team could use in-house.
-
eCOA And Digital Platforms Reduce Diabetes Study Startup To 8 Weeks
See how digital solutions came together to enable faster study startup by 50% for this top pharma company conducting a Phase 3 diabetes study within the weight loss market.
-
Agentic AI Is Reshaping Clinical Monitoring And The CRA Role Again
See why this isn't about replacing CRAs, but freeing them from the admin grind so they can focus on judgment, site relationships, and the work that actually moves trials forward.
-
How Protocol Design Decisions Shape Recruitment, Data Quality & Study Startup
Protocol design directly affects recruitment, data quality, and startup speed. Clear workflows, streamlined criteria, and early alignment reduce delays, amendments, and improve reliable study execution.
-
Navigating eCOA Licensing And Localization In Clinical Trials
eCOA has been key in trials for 20 years, but issues like licensing, localization, and execution quality still challenge sponsors.
- Why The Biostatistician's Seat At The Table Keeps Vanishing
- From 73% Noncompliant To 2.4%: Building A Compliance Office
- How AI Is Used To Predict Trial Performance Before Enrollment
- Two Planning Mistakes That Quietly Sink Clinical Programs
- A Framework For Diagnosing Clinical Research Technology Maturity
RECENT NEWSLETTERS
- 09.24.26 -- AI, Wearables, And CRA Workflows Are Exposing Trial Gaps
- 09.17.26 -- AI, Wearables, And eTMF Are Exposing Trial Data Gaps
- 09.10.26 -- AI, Trial Costs, And RTSM Are Reshaping Clinical Operations
- 09.05.26 -- Best Of August: AI, FDA RWE, And Trial Data Risks
- 09.03.26 -- AI, APIs, and eConsent Are Exposing Trial Workflow Gaps